SEC Company Response from Galmed Pharmaceuticals Ltd. (GLMD) (CIK 0001595353) (EOCN) — Jun 29, 2015
Galmed Pharmaceuticals Ltd. (GLMD) (CIK 0001595353)
Date: June 29, 2015 · CIK: 0001595353 · Accession: 0001144204-15-039701
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-203133
Letter
Re: Galmed Pharmaceuticals Ltd.
June 29, 2015
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Registration Statement on Form F-3 (Registration No. 333-203133)
Acceleration Request
Requested Date: Wednesday, July 1, 2015
Requested Time: 4:00 p.m. Eastern Time
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Galmed Pharmaceuticals Ltd. (the “Registrant”) hereby requests that the above-referenced Registration Statement on Form F-3 (the “Registration Statement”) be declared effective at the “Requested Date” and “Requested Time” set forth above or at such later time as the Registrant or its counsel may orally request via telephone call to the staff (the “Staff”) of the Division of Corporation Finance of the Securities and Exchange Commission (the “Commission”) (the “Registration Statement Acceleration Request”). The Registrant hereby authorizes Scott A. Cowan, Esq. of DLA Piper LLP (US), counsel for the Registrant, to make such request on the Registrant’s behalf.
In connection with the acceleration request, the Registrant hereby acknowledges that:
· should the Commission or the Staff, acting pursuant to delegated authority, declare the Registration Statement effective, it does not foreclose the Commission from taking any action with respect to the Registration Statement;
· the action of the Commission or the Staff, acting pursuant to delegated authority, in declaring the Registration Statement effective, does not relieve the Registrant from its full responsibility for the adequacy and accuracy of the disclosure in the Registration Statement; and
· the Registrant may not assert Staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
We request that we be notified of the effectiveness of the Registration Statement by telephone to Scott A. Cowan of DLA Piper LLP (US) at 973-520-2554. Please also provide a copy of the Commission’s order declaring the Registration Statement effective to Scott A. Cowan via facsimile at 973-520-2574. Thank you for your assistance.
Very truly yours,
/s/ Allen Baharaff
Show Raw Text
CORRESP 1 filename1.htm June 29, 2015 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Galmed Pharmaceuticals Ltd. Registration Statement on Form F-3 (Registration No. 333-203133) Acceleration Request Requested Date: Wednesday, July 1, 2015 Requested Time: 4:00 p.m. Eastern Time Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Galmed Pharmaceuticals Ltd. (the “Registrant”) hereby requests that the above-referenced Registration Statement on Form F-3 (the “Registration Statement”) be declared effective at the “Requested Date” and “Requested Time” set forth above or at such later time as the Registrant or its counsel may orally request via telephone call to the staff (the “Staff”) of the Division of Corporation Finance of the Securities and Exchange Commission (the “Commission”) (the “Registration Statement Acceleration Request”). The Registrant hereby authorizes Scott A. Cowan, Esq. of DLA Piper LLP (US), counsel for the Registrant, to make such request on the Registrant’s behalf. In connection with the acceleration request, the Registrant hereby acknowledges that: · should the Commission or the Staff, acting pursuant to delegated authority, declare the Registration Statement effective, it does not foreclose the Commission from taking any action with respect to the Registration Statement; · the action of the Commission or the Staff, acting pursuant to delegated authority, in declaring the Registration Statement effective, does not relieve the Registrant from its full responsibility for the adequacy and accuracy of the disclosure in the Registration Statement; and · the Registrant may not assert Staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. We request that we be notified of the effectiveness of the Registration Statement by telephone to Scott A. Cowan of DLA Piper LLP (US) at 973-520-2554. Please also provide a copy of the Commission’s order declaring the Registration Statement effective to Scott A. Cowan via facsimile at 973-520-2574. Thank you for your assistance. Very truly yours, /s/ Allen Baharaff Allen Baharaff President and Chief Executive Officer cc: Via E-mail Scott A. Cowan, Esq., DLA Piper LLP (US) EAST\101479392.1